ガイドライン

(旧版)科学的根拠に基づく
膵癌診療ガイドライン 2006年版

書誌情報
 
CQ2 化学療法


CQ2-4 切除不能膵癌に対して推奨される二次化学療法は何か?

【引用文献】
1) Oettle H, Arnold D, Esser M, Huhn D, Riess H. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 2000; 11: 635-638.
2) Kozuch P, Grossbard ML, Barzdins A, Araneo M, Robin A, Frager D, Homel P, Marino J, DeGregorio P, Bruckner HW. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 2001; 6: 488-495.
3) Milella M, Gelibter A, Di Cosimo S, Bria E, Ruggeri EM, Carlini P, Malaguti P, Pellicciotta M, Terzoli E, Cognetti F. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 2004; 101: 133-138.
4) Reni M, Panucci MG, Passoni P, Bonetto E, Nicoletti R, Ronzoni M, Zerbi A, Staudacher C, Di Carlo V, Villa E. Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial. Cancer Invest 2004; 22: 688-696.
5) Cantore M, Rabbi C, Fiorentini G, Oliani C, Zamagni D, Iacono C, Mambrini A, Del Freo A, Manni A. Combined irinotecan and oxiliplatin in patients with advanced pre-treated pancreatic cancer. Oncology 2004; 67: 93-97.
6) Ulrich-Pur H, Raderer M, Verena Kornek G, Schull B, Schmid K, Haider K, Kwasny W, Depisch D, Schneeweiss B, Lang F, Scheithauer W. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 2003; 88: 1180-1184.
7) Oettle H, Pelzer U, Stieler J, Hilbig A, Roll L, Schwaner I, Adler M, Detken S, Dorken B, Riess H. Oxaliplatin/folinic acid/5-fluorouracil[24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003) . Proc Am Soc Clin Oncol 2005; 23: 4031 (abstract) .
8) Jacobs AD, Burris HA, Rivkin S, Ritch PS, Eisenberg PD, Mettinger KL. A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study. J Clin Oncol 2004; 22: 4013 (abstract) .
9) Funakoshi A, Okusaka T, Ishii H, Sawaki A, Ishikawa O, Ohkawa S, Saitoh S. Phase II study of Irinotecan (CPT-11) alone in patients with metastatic pancreatic cancer. Proc Am Soc Clin Oncol 2004; 22: 4102 (abstract) .
10) Furuse J, Okusaka T, Funakoshi A, Boku N, Yamao K, Ohkawa S, Saito H. A phase II study of S-1 in patients with metastatic pancreatic cancer. Proc Am Soc Clin Oncol 2005; 23: 4104 (abstract) .


 

書誌情報